Page 2 - பிரிவு ஆஃப் பொது ஆரோக்கியம் அறிவியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers Looking Into Link Between COVID Vaccine and Menstruation

It’s a question researcher Katherine Lee asked after her own experience. ”I had spotting when I normally don t have any sort of menstrual symptoms, because I have the Mirena IUD,” said Lee, a postdoctoral research scholar in the Division of Public Health Sciences at the Washington University School of Medicine in St. Louis. Lee reached out to Kate Clancy, an associate professor of Anthropology at the University of Illinois, who then tweeted about it. “That tweet was sent February 24th, and I m still getting, like, every minute an additional 20 notifications, that have some kind of engagement with that thread two months later,” Clancy said.

Anne thompsonElizabeth yepezKatherine leeKate clancyUniversity of illinoisRush university medical centerWashington university school of medicineDivision of public health sciencesPublic health sciencesWashington university schoolRush university medicalஅன்னே தாம்சன்க்யாதரிந் லீகேட் குலம்பல்கலைக்கழகம் ஆஃப் இல்லினாய்ஸ்அவசரம் பல்கலைக்கழகம் மருத்துவ மையம்

Giving chemotherapy in the morning can extend survival of glioblastoma patients

Giving chemotherapy in the morning can extend survival of glioblastoma patients An aggressive type of brain cancer, glioblastoma has no cure. Patients survive an average of 15 months after diagnosis, with fewer than 10% of patients surviving longer than five years. While researchers are investigating potential new therapies via ongoing clinical trials, a new study from Washington University in St. Louis suggests that a minor adjustment to the current standard treatment -; giving chemotherapy in the morning rather than the evening -; could add a few months to patients survival. The study appears online in the journal Neuro-Oncology Advances. Average overall survival for all patients in the study was about 15 months after diagnosis. Those receiving the chemotherapy drug temozolomide in the morning had an average overall survival of about 17 months post diagnosis, compared with an average overall survival of about 13½ months for those taking the drug in the evening, a statistically

Annar damatoJoshuab rubinJianl campianErikd herzogEmily hendersonSchool of medicineSiteman cancer center biostatistics shared resourceSiteman cancer center at barnesDivision of biology biomedical sciencesWashington university school of medicineArts sciencesDivision of public health sciencesBrain tumor center at sitemanWashington university in stWashington universityWashington university school

Study indicates timing of chemotherapy may improve treatment for glioblastoma - World News

Study indicates timing of chemotherapy may improve treatment for glioblastoma - World News
sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.

United statesErik herzogSiteman cancer center biostatistics shared resourceSiteman cancer center at barnesWashington university school of medicineWashington university in stDivision of public health sciencesWashington universitySiteman cancer centerBarnes jewish hospitalWashington university schoolPublic health sciencesSiteman cancer center biostatistics sharedஒன்றுபட்டது மாநிலங்களில்ஏறிக் ஹெர்சாக்வாஷிங்டன் பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து

Chemo for glioblastoma may work better in morning than evening | The Source | Washington University in St Louis

Chemo for glioblastoma may work better in morning than evening | The Source | Washington University in St Louis
wustl.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wustl.edu Daily Mail and Mail on Sunday newspapers.

Annar damatoJoshuab rubinJianl campianErikd herzogSchool of medicineSiteman cancer center biostatistics shared resourceSiteman cancer center at barnesDivision of biology biomedical sciencesWashington university school of medicineSiteman cancer centerArts sciencesDivision of public health sciencesBrain tumor center at sitemanWashington university in stWashington universityViktor hamburger distinguished professor

Projection of cancer screening on metastasis: A prostate cancer case study

Projection of cancer screening on metastasis: A prostate cancer case study From the Etzioni Group, Public Health Sciences Division March 15, 2021 • By Coco Davis / Fred Hutchinson Cancer Research Center One of the main purposes of cancer screening is to detect localized tumors early to reduce cancer mortality. The belief or prediction that early detection will decrease the likelihood of advanced-stage cancer is called “stage shift”. Unfortunately, stage shift doesn’t consider progressive cases after diagnosis. Additionally, the diagnosis of advanced-stage cancer with screening does not always reduce disease-specific deaths. The reduction of advanced-stage cases at diagnosis will become organ-confined cases and increase the number of cases eligible for metastasis. Also, progressive cases may reduce the incidence of metastatic disease at diagnosis, resulting in the same number of metastatic cases in a screened and non-screened group.

Fred hutchEtzioni group fred hutchDivision of public health sciencesEtzioni groupPublic health sciencesMedical screeningEuropean randomized screeningProstate cancerScandanavian prostate cancerProstate specific antigenCancer screeningஃப்ரெட் ஹட்ச்பிரிவு ஆஃப் பொது ஆரோக்கியம் அறிவியல்பொது ஆரோக்கியம் அறிவியல்மருத்துவ திரையிடல்ப்ராஸ்டேட் புற்றுநோய்